Company Overview and News

19
Market Update: Pharma stocks extend gains with Lupin up 5%; TCS, RIL most active

2018-06-12 moneycontrol
The broader indices are trading on a positive note this Tuesday afternoon with the Nifty trading higher by 47 points at 10,834 and the Sensex added 177 points at 35,661.
500408 500325 AUROPHARMA RELIANCE TTQQY 532714 HINDUNILVR 511389 VIDEOIND IDBLZ HCL-INSYS CADILAHC TATACHEM 532960 JUSTDIAL 532321 535648 532187 532483 RIGD 500696 500179 BJJQY KEC 500770 RLNIY 500034 SBAZ UBNC 524804 INDUSINDBK IBVENTURES CDLYY CNRYY BAJFINANCE ARBQY TATAELXSI CANBK JSTQY

4
Tata Chemicals Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TTQQY 500770 TATACHEM

26
Market Live: Sensex mildly lower; all sectoral indices in the red except Auto

2018-06-01 moneycontrol
Market Update: The market continued to be mildly under pressure amid consolidation, but European stocks are strong in trade after Italy agreed to form a government.
BAJAJ-AUTO 539150 513262 500325 GAYAPROJ RELIANCE TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 531795 505200 532343 RIGD HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 RLNIY ASHOKLEY ECQRY TVSMOTOR IBN ATULAUTO 532767 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS MARUTI 532174 HRTQY AKLS SSWL TTM

4
Tata Chemicals exits fertiliser biz; completes sale of Haldia unit

2018-06-01 moneycontrol
Tata Chemicals today said it has completed the sale of its Haldia fertiliser unit in West Bengal and the trading business to Netherlands-based Indorama Holdings BV for Rs 872.84 crore.
TTQQY 500770 TATACHEM

29
Market Live: Sensex mildly lower, Midcaps underperform; HDFC Bank drags, Eicher Motors dips 4%

2018-06-01 moneycontrol
Allahabad High Court on Power NPAs: Allahabad High Court has stayed the Reserve Bank of India’s February 12 circular on resolution on non-performing assets (NPAs) for the assets in the power sector.
BAJAJ-AUTO 539150 513262 GAYAPROJ TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 531795 505200 533106 OIL HDFCBANK HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 ASHOKLEY ECQRY IBN ATULAUTO 532767 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS HDB MARUTI 532174 500180 HRTQY AKLS SSWL TTM

23
Market Live: Nifty holds 10,700 amid consolidation; Bajaj Auto extends rally

2018-06-01 moneycontrol
Market Update: The market continued to be rangebound as investors digested better-than-expected Q4 GDP data, which shows India is the fastest growing economy, and shifted focus to global trade concerns, and the movement in crude oil prices & rupee.
BAJAJ-AUTO 539150 TTQQY 530239 PNCINFRA 532977 SUVEN TATACHEM 505200 533106 GRANULES OIL 532482 HEROMOTOCO 500477 500570 TATAMOTORS EICHERMOT 500770 ASHOKLEY ECQRY IBN 532843 MRZUY AKLD 532500 500182 ICICIBANK FORTIS MARUTI 532174 HRTQY AKLS TTM

4
Tata Chemicals Limited - Updates

2018-06-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TTQQY 500770 TATACHEM

4
Tata Chemicals Limited - Updates

2018-05-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
TTQQY 500770 TATACHEM

4
Tata Chemicals net up 23 per cent in Q4

2018-05-22 freepressjournal.in
Mumbai : Tata Chemicals reported a 23.37 per cent growth in consolidated net profit for the March quarter at Rs 355.90 crore, mainly driven by healthy margins in chemicals, soda ash and salt business and gains from sale of its urea business to Yara Fertilisers India.
TTQQY 500770 TATACHEM

4
Tata Chemicals posts 4-fold jump in Q4 profit

2018-05-19 freepressjournal.in
New Delhi : Tata Chemicals on Friday posted a nearly four-fold jump in consolidated net profit at Rs 1,168.60 crore for the fourth quarter of 2017-18 largely on the back of exceptional gains from sale of its urea business to Yara Fertilisers India.
TTQQY 500770 TATACHEM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

13h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...